Pharma BD Deal Intelligence
Merck acquired Cubist Pharmaceuticals for $9.5B, an antibiotic-focused pharmaceutical firm.
Combining Cubist's antibiotic expertise with Merck's global reach will strengthen the company's position in hospital acute care, with the deal expected to add…
Merck to acquire Cubist Pharmaceuticals for $102 per share in cash, representing a 35% premium to Cubist's average stock price, with total transaction value of…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Merck acquired Cubist Pharmaceuticals for $9.5B, an antibiotic-focused pharmaceutical firm.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Cubist Pharmaceuticals, Inc. (this deal) | 2014 | $9.5B | 41 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2014 deals · Merck & Co. Inc. deals · Infectious Disease deals